Dov Weinberger - research works

She was diagnosed with macular detachment secondary to optic nerve head pit in her right eye and bilateral chorioretinal coloboma.

The cohort included 106 eyes of 102 patients.

No other complications related to the absence of prophylactic corneal sutures were encountered during surgery or follow-up.

In the study group, staining for tPA was detected in the deep retinal layers in all eyes.

The staining was deeper and more intense at 3 and 24 h than at 48 h.

There was no tPA staining in the retina of eyes injected with saline.

The duration of perfluorocarbon tamponade ranged from 6 to 13 days (mean ± SD 10 ± 2 days).

Follow-up time ranged from 3 to 44 months (mean ± SD 11 ± 11 months).

Retinal reattachment was achieved intraoperatively in all patients.

Repeated detachment with proliferative vitreoretinopathy occurred in one patient (8%), who underwent repeated vitrectomies.

Massive influx of CD11+ inflammatory cells, involving the anterior and posterior chambers, was observed in the murine eyes 24 h after the IL-8 or TNF-α injections.

Cells excreted to their surroundings an extracellular net-like structure positive for NE, MPO, and H3Cit.

H3Cit staining was abolished with the DNase I treatment, indicating the presence of extracellular DNA in the net-like structures.

The etiology of sustained ocular hypertension following intravitreal administration of anti-VEGF agents is yet to be unraveled.

Bevacizumab (25 mg/ml) was injected intravitreally after 3 days.

Donkey anti-human IgG labeled with Alexa Fluor(®) 488 was used for bevacizumab immunoreactivity detection.

Anti-CD31 antibody was used as a marker for Schlemm's canal endothelial cells.

The large majority of patients (70.4%) were referred due to glaucoma, ocular hypertension or suspected glaucoma.

Most of the patients had threshold strategies: FastPac 24-2 or 30-2 (88.9%), Full Threshold (0.7%), and 10-2 (0.5%).

In only 7 patients was short-wavelength automated perimetry (SWAP) performed.

The Swedish Interactive Testing Algorithm (SITA) was applied in 1.0% of cases.

Seven patients received additional treatment based on the underlying condition.

Mean macular thickness on optical coherence tomography decreased from 394 +/- 116 microm to 254 +/- 52 microm (P < 0.01).

Mean visual acuity improved from 0.87 +/- 0.74 logarithm of the minimum angle of resolution to 0.38 +/- 0.63 (P = 0.005).

Thirty-two eyes were treated previously with photodynamic therapy.

Snellen visual acuity improved from 20/150 to hand movements (mean logMAR 1.34 +/- 0.29) to 20/50 to counting fingers (mean logMar 1.2 +/- 0.42) (P = 0.003, paired t-test).

Visual acuity improved by> or =3 lines in 12 eyes (25%); showed no change in 9 eyes (19%); and deteriorated by > or =3 lines in 4 eyes (8.3%).

Mean central retinal thickness (measured in 22 eyes) decreased from 324 +/- 121 mum to 264 +/- 65 mum (P = 0.02, paired t-test).

The group included 100 neonates (194 eyes) with a mean birth weight +/- SD of 833.9 +/- 250.3 g and a mean gestational age +/- SD of 26 +/- 1.9 weeks.

Each eye received a mean +/- SD of 1,740 +/- 990 laser applications, and 21% of eyes received an additional 1 to 2 rows posterior to the ridge.

Neonates treated after December 2003 (cutoff date of the Early Treatment of Retinopathy of Prematurity study) underwent a significantly greater number of laser applications (mean +/- SD, 2,286 +/- 1,087) than did neonates treated earlier.

Refractive data were available for 134 eyes: 55.2% had myopia of -5 diopters (31.3%) or greater (23.9%).

The mean age was 63.1 years.

Patients received a mean of 3.48 treatments.

Mean VA improved in the younger group from 0.63 to 0.39 logMAR (P = .02, paired t test) and deteriorated in the older group from 0.71 to 0.99 logMAR (P = .03, paired t test).

Homocysteine levels were higher by 27.9% in the neovascular AMD than in the dry AMD group, and by 21.9% than in the control group (P <.02).